Compounds > alacepril
Page last updated: 2024-09-23

alacepril

Cross-References

ID SourceID
PubMed CID71992
CHEMBL ID2103775
CHEBI ID31182
SCHEMBL ID34559
MeSH IDM0135521

Synonyms (44)

Synonym
du-1219
cetapril
alacepril
n-(2-((s)-3-acetylthio-2-methylpropionyl)propyl)-3-phenylalanin
l-phenylalanine, n-(1-(3-(acetylthio)-2-methyl-1-oxopropyl)-l-prolyl)-, (s)-
alaceprilum [latin]
n-(1-((s)-3-mercapto-2-methylpropionyl)-l-prolyl)-3-phenyl-l-alanine acetate (ester)
nsc 338157
1-(d-3-acetylthio-2-methylpropanoyl)-l-prolyl-l-phenylalanine
brn 3634372
alacepril [inn:jan]
du 1219
74258-86-9
nsc-338157
D01900
cetapril (tn)
alacepril (jp17/inn)
(2s)-2-[[(2s)-1-[(2s)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
NCGC00182037-01
dtxsid3048576 ,
tox21_112904
dtxcid3028502
cas-74258-86-9
CHEMBL2103775
x39tl7jdpf ,
unii-x39tl7jdpf
alaceprilum
AKOS015916655
1-((2s)-3-(acetylthio)-2-methyl-1-oxopropyl)-l-prolyl-l-phenylalanine
alacepril [inn]
alacepril [mart.]
alacepril [who-dd]
alacepril [mi]
alacepril [jan]
SCHEMBL34559
KS-1321
FHHHOYXPRDYHEZ-COXVUDFISA-N
1-[(2s)-3-(acetylthio)-2-methyl-1-oxopropyl]-l-prolyl-l-phenylalanine
CHEBI:31182
(s)-2-((s)-1-((s)-3-(acetylthio)-2-methylpropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoic acid
Q3290792
219554-02-6
HY-107318
CS-0028129

Research Excerpts

Overview

ExcerptReference
"Alacepril is a relatively novel angiotensin-converting enzyme inhibitor; however, the safety, tolerance, and efficacy of alacepril in terms of cough suppression in dogs with mitral valve disease (MVD) remain unknown. "( Hitomi, M; Hori, Y; Hosaka, S; Isayama, N; Kanno, N; Mimura, T; Nakamura, K; Yamashita, Y, 2018)
"1. Alacepril is a long-acting, sulphydryl-containing angiotensin-converting enzyme inhibitor. "( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Tomikura, Y, 2002)
"Alacepril is an inhibitor of the angiotensin converting enzyme (ACE), and is commonly used as an antihypertensive. "( Mori, A; Noda, Y; Packer, L, 1997)

Treatment

ExcerptReference
"Alacepril as treatment for MVD is well tolerated in most dogs, and different conditions of cardiac loading may influence the effect of the drug."( Hitomi, M; Hori, Y; Hosaka, S; Isayama, N; Kanno, N; Mimura, T; Nakamura, K; Yamashita, Y, 2018)
"Alacepril treatment not only dose-relatedly lowered mean blood pressure, but also dose-relatedly improved abnormalities in carbohydrate and lipid metabolism in STZ-induced diabetic SHR."( Kato, Y; Nara, Y; Sato, T; Yamori, Y, 1996)
"3. Treatment with alacepril significantly improved NYHA functional class and decreased cardiothoracic ratio (60.1 +/- 2.0 vs 58.1 +/- 1.9% for baseline vs alacepril, respectively; P < 0.01)."( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Tomikura, Y, 2002)
"Pretreatment with alacepril reduced the enhanced expression of these molecules in a dose-dependent manner."( Katada, K; Kuroda, M; Manabe, H; Naito, Y; Nakabe, N; Shimozawa, M; Uchiyama, K; Yoshida, N; Yoshikawa, T, 2004)
"Oral treatment with Alacepril was begun on confirmation of atherosclerosis after a three month high cholesterol diet (group AL)."( Itoh, K; Yoshida, S, 1994)

Roles (1)

RoleDescription
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
thioacetate esterA compound of general formula CH3C(=O)SR where R is an organyl group.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.48660.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency21.31740.01238.964839.8107AID1645842
thyroid stimulating hormone receptorHomo sapiens (human)Potency18.83360.001628.015177.1139AID1259385
Interferon betaHomo sapiens (human)Potency21.31740.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (20.25)18.7374
1990's35 (44.30)18.2507
2000's11 (13.92)29.6817
2010's11 (13.92)24.3611
2020's6 (7.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (11.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (4.71%)4.05%
Observational0 (0.00%)0.25%
Other71 (83.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
pyrrolidonecarboxylic acid[no description available]medium10oxoproline;
pyrrolidin-2-ones;
pyrrolidinemonocarboxylic acid		human metabolite
pipecolic acid[no description available]medium10piperidinemonocarboxylic acid
acetanilide[no description available]medium10acetamides;
anilide		analgesic
phenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
salophen[no description available]medium10carbonyl compound
Acetylpheneturide[no description available]medium10organic molecular entity
albendazole[no description available]medium10aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
4-amino-3-hydroxybutyric acid[no description available]medium103-hydroxy monocarboxylic acid;
amino acid zwitterion;
gamma-amino acid
amlexanox[no description available]medium10monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine[no description available]medium30dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
arecoline[no description available]medium10enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
aristolochic acid i[no description available]medium10aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin
arotinolol[no description available]medium10aromatic amide;
thiophenes
atenolol[no description available]medium10ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
benzocaine[no description available]medium10benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
biperiden[no description available]medium10piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bupivacaine[no description available]medium10aromatic amide;
piperidinecarboxamide;
tertiary amino compound
verapamil[no description available]medium20aromatic ether;
nitrile;
polyether;
tertiary amino compound
cannabinol[no description available]medium10dibenzopyran
carbamazepine[no description available]medium10dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbetapentane[no description available]medium10benzenes
clobazam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clonazepam[no description available]medium101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
cycloleucine[no description available]medium10non-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor
cyclothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
dimethadione[no description available]medium10oxazolidinone
valproic acid[no description available]medium10branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
ethosuximide[no description available]medium10dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
felbamate[no description available]medium10carbamate esteranticonvulsant;
neuroprotective agent
felodipine[no description available]medium10dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
gabapentin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glutethimide[no description available]medium10piperidines
guvacine[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
beta-amino acid;
pyridine alkaloid;
secondary amino compound;
tetrahydropyridine		GABA reuptake inhibitor;
plant metabolite
ifosfamide[no description available]medium10ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
iproniazid[no description available]medium10carbohydrazide;
pyridines
lamotrigine[no description available]medium101,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
mephenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
metharbital[no description available]medium10organic molecular entity
moclobemide[no description available]medium10benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
acecainide[no description available]medium10acetamides;
benzamides		anti-arrhythmia drug
deoxyepinephrine[no description available]medium10catecholamine
nicardipine[no description available]medium50benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nicardipine[no description available]medium52benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium10C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimetazepam[no description available]medium101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
GABA modulator;
sedative
nimodipine[no description available]medium102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nipecotic acid[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid
nisoldipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam[no description available]medium101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
phenacemide[no description available]medium10acetamides
phenobarbital[no description available]medium10barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
primidone[no description available]medium10pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
riluzole[no description available]medium20benzothiazoles
sulfanilamide[no description available]medium10substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulthiame[no description available]medium10organic molecular entity
trimethadione[no description available]medium10oxazolidinoneanticonvulsant;
geroprotector
vigabatrin[no description available]medium10gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
zonisamide[no description available]medium101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
prednisolone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
carbachol[no description available]medium10ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
metaraminol[no description available]medium10phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
desoxycorticosterone acetate[no description available]medium10corticosteroid hormone
physostigmine[no description available]medium10carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
ampicillin[no description available]medium10beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
phencyclidine[no description available]medium10benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
caramiphen[no description available]medium10benzenes
methsuximide[no description available]medium10organic molecular entity
phthalimide[no description available]medium10phthalimides
phensuximide[no description available]medium10pyrrolidines
amido-g-acid[no description available]medium10
cyclopentamine[no description available]medium10secondary amino compound
caprolactam[no description available]medium10caprolactamshuman blood serum metabolite
mephobarbital[no description available]medium10barbituratesanticonvulsant
paramethadione[no description available]medium10oxazolidinoneanticonvulsant
cyclopentanone[no description available]medium10cyclopentanonesMaillard reaction product
benactyzine[no description available]medium10diarylmethane
phetharbital[no description available]medium10barbiturates
prenylamine[no description available]medium10diarylmethane
beclamide[no description available]medium10benzenes
chlormethiazole[no description available]medium10thiazoles
glybuthiazol[no description available]medium10benzenes;
sulfonamide
pronarcon[no description available]medium10barbiturates
improsan[no description available]medium10organosulfonic ester
iproclozide[no description available]medium10aromatic ether
aminopentamide[no description available]medium10diarylmethane
benomyl[no description available]medium10aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
alclofenac[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carticaine[no description available]medium10thiophenecarboxylic acid
amoscanate[no description available]medium10C-nitro compound;
isothiocyanate;
secondary amino compound		schistosomicide drug
amoxicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
eterobarb[no description available]medium10barbiturates
adinazolam[no description available]medium10triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
diltiazem[no description available]medium105-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
progabide[no description available]medium10diarylmethane
lidamidine[no description available]medium10ureas
acifran[no description available]medium10
tiagabine[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
d-lactic acid[no description available]medium102-hydroxypropanoic acidEscherichia coli metabolite;
human metabolite
heptenophos[no description available]medium10organochlorine compound;
organophosphate insecticide;
trialkyl phosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
trihexyphenidyl hydrochloride[no description available]medium10aralkylamine
g 29505[no description available]medium10methoxybenzenes
acefylline[no description available]medium10oxopurine
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
aceclofenac[no description available]medium10amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
amphotalide[no description available]medium10phthalimides
fluoresone[no description available]medium10sulfonamide
agroclavine[no description available]medium10ergot alkaloid
n-(hydroxymethyl)nicotinamide[no description available]medium10pyridinecarboxamide
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
camphora[no description available]medium10camphor
tevenel[no description available]medium10sulfonamide
fluoracizine[no description available]medium10phenothiazines
ritonavir[no description available]medium101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
arbutin[no description available]medium10beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
cannabidiol[no description available]medium10olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
cinromide[no description available]medium10cinnamamides;
secondary carboxamide
flunarizine[no description available]medium10diarylmethane
benztropine[no description available]medium10diarylmethane
albutoin[no description available]medium10organonitrogen compound;
organooxygen compound
adrafinil[no description available]medium10diarylmethane
linoleic acid[no description available]medium10octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
gemeprost[no description available]medium10aliphatic alcohol
topiramate[no description available]medium10cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
furazolidone[no description available]medium10
zr-512[no description available]medium10ethyl ester;
farnesane sesquiterpenoid		juvenile hormone mimic
nidroxyzone[no description available]medium10C-nitro compound;
furans
azimilide[no description available]medium10imidazolidine-2,4-dione
scopolamine hydrobromide[no description available]medium10
imidacloprid[no description available]medium10imidacloprid;
imidazolidines;
monochloropyridine		environmental contaminant;
genotoxin;
neonicotinoid insectide;
nicotinic acetylcholine receptor agonist;
xenobiotic
pk 11195[no description available]medium10aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
pd 173074[no description available]medium10aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
abt 702[no description available]medium10bipyridines
bicalutamide[no description available]medium10(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
celecoxib[no description available]medium10organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chelerythrine[no description available]medium10benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
furosemide[no description available]medium10chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gossypol[no description available]medium10
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
indirubin-3'-monoxime[no description available]medium10
leflunomide[no description available]medium10(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole[no description available]medium10nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lg 100268[no description available]medium10
metformin[no description available]medium10guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
mitoxantrone[no description available]medium10dihydroxyanthraquinoneanalgesic;
antineoplastic agent
entinostat[no description available]medium10benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
olprinone[no description available]medium10bipyridines
omeprazole[no description available]medium10aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
pioglitazone[no description available]medium10aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one[no description available]medium10indoles
sb 206553[no description available]medium10pyrroloindole
sb 220025[no description available]medium10aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190[no description available]medium10imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sk&f 86002[no description available]medium10imidazoles
imatinib[no description available]medium10aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat[no description available]medium10dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfasalazine[no description available]medium10
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine[no description available]medium10stilbenoid
troglitazone[no description available]medium20chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
azacitidine[no description available]medium10N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
podophyllotoxin[no description available]medium10furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
formestane[no description available]medium1017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
hydroxychloroquine sulfate[no description available]medium10
amiloride hydrochloride, anhydrous[no description available]medium10hydrochloridediuretic;
sodium channel blocker
acadesine[no description available]medium101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
cladribine[no description available]medium10organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
zidovudine[no description available]medium10azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lonidamine[no description available]medium10dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
simvastatin[no description available]medium10delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
itraconazole[no description available]medium10aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
pravadoline[no description available]medium10
zileuton[no description available]medium101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
niguldipine[no description available]medium10diarylmethane
topotecan[no description available]medium10pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil[no description available]medium10monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
gemcitabine[no description available]medium10organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
verapamil hydrochloride[no description available]medium10
efavirenz[no description available]medium10acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
bendamustine[no description available]medium10benzimidazoles
caroverine[no description available]medium10quinoxaline derivative
cgs 9343b[no description available]medium10benzimidazoles
telmisartan[no description available]medium20benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
2-methoxyestradiol[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
ubenimex[no description available]medium10
vinpocetine[no description available]medium10
deguelin[no description available]medium10aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
triptolide[no description available]medium10diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
sr 48692[no description available]medium10N-acyl-amino acid
elacridar[no description available]medium10
gefitinib[no description available]medium10aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
bay x 1005[no description available]medium10
gyki 53655[no description available]medium10
ml-3000[no description available]medium10
cd 437[no description available]medium10adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols		apoptosis inducer;
retinoic acid receptor gamma agonist
docetaxel anhydrous[no description available]medium10secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
perifosine[no description available]medium10ammonium betaine;
phospholipid		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
mk 767[no description available]medium10
bazedoxifene acetate[no description available]medium10
canertinib[no description available]medium10monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
birb 796[no description available]medium10aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
tipifarnib[no description available]medium10imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202[no description available]medium102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580[no description available]medium10imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
enzastaurin[no description available]medium10indoles;
maleimides
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
piboserod[no description available]medium10
l 163191[no description available]medium10
bd 1047[no description available]medium10primary amine
lapatinib[no description available]medium10furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lenalidomide[no description available]medium10aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide[no description available]medium10aminoquinoline
sr 142806[no description available]medium10
elesclomol[no description available]medium10carbohydrazide;
thiocarbonyl compound		antineoplastic agent;
apoptosis inducer
nsc 663284[no description available]medium10quinolone
bortezomib[no description available]medium10amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
bardoxolone methyl[no description available]medium10cyclohexenones
nsc 23766[no description available]medium10aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound		antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
gw 3965[no description available]medium10diarylmethane
y 27632[no description available]medium10aromatic amide
6-bromoindirubin-3'-oxime[no description available]medium10
purvalanol b[no description available]medium10purvalanolprotein kinase inhibitor
y-700[no description available]medium10
repsox[no description available]medium10pyrazolopyridine
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide[no description available]medium10tropane alkaloid
s 1033[no description available]medium10(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
mercaptopurine[no description available]medium10aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
rg108[no description available]medium10indolyl carboxylic acid
stf 083010[no description available]medium10
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide[no description available]medium10naphthalenecarboxamide
cct018159[no description available]medium10benzodioxine;
pyrazoles;
resorcinols		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
secinh3[no description available]medium10triazoles
jk184[no description available]medium10
tamoxifen citrate[no description available]medium10citrate saltangiogenesis inhibitor;
anticoronaviral agent
hc-067047[no description available]medium10
bi-78d3[no description available]medium10aryl sulfide
gsk 3787[no description available]medium10
methyl-thiohydantoin-tryptophan[no description available]medium10organonitrogen compound;
organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester[no description available]medium10monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide[no description available]medium10sulfonamide
LSM-1318[no description available]medium10oxa-steroid
rwj 67657[no description available]medium10
6-methyl-2-(phenylethynyl)pyridine[no description available]medium10acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
bms 387032[no description available]medium101,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
tandutinib[no description available]medium10aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745[no description available]medium10aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor[no description available]medium10hydrochloridecardiotonic drug
dasatinib[no description available]medium101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
zd 6474[no description available]medium10aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
compound 968[no description available]medium10benzophenanthridineEC 3.5.1.2 (glutaminase) inhibitor
sb-224289[no description available]medium101,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
gw 7647[no description available]medium10aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
l 663536[no description available]medium10aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine[no description available]medium10imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine[no description available]medium10aromatic amine;
tertiary amino compound
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester[no description available]medium10isoquinolines
sch 79797[no description available]medium10quinazolines
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide[no description available]medium10benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one[no description available]medium10monobactam
imd 0354[no description available]medium10benzamides
ex 527[no description available]medium10carbazoles;
monocarboxylic acid amide;
organochlorine compound
quercetin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
genistein[no description available]medium107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
fenretinide[no description available]medium10monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
ter 199[no description available]medium10
arachidonylcyclopropylamide[no description available]medium10
ly 320135[no description available]medium10benzofurans
pd 166285[no description available]medium10
kn 62[no description available]medium10piperazines
su 6656[no description available]medium10
semaxinib[no description available]medium10olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
su 11248[no description available]medium10monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
palbociclib[no description available]medium10aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621[no description available]medium10sulfonamide
cisplatin[no description available]medium10diamminedichloroplatinumantineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent
vx680[no description available]medium10N-arylpiperazine
d 4476[no description available]medium10imidazoles
cyc 116[no description available]medium10
bay 19-8004[no description available]medium10
axitinib[no description available]medium10aryl sulfide;
benzamides;
indazoles;
pyridines		antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
pai 039[no description available]medium10indole-3-acetic acids
gw2974[no description available]medium10pyridopyrimidine
ispinesib[no description available]medium10benzamides
temsirolimus[no description available]medium10macrolide lactam
pd 184352[no description available]medium10aminobenzoic acid
bibx 1382bs[no description available]medium10substituted aniline
hdac-42[no description available]medium10amidobenzoic acid
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone[no description available]medium10benzamides;
N-acylpiperidine
iniparib[no description available]medium10carbonyl compound;
organohalogen compound
mk 0752[no description available]medium10
gw 501516[no description available]medium101,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
av 412[no description available]medium10
ag-041r[no description available]medium10
telatinib[no description available]medium10
cp 547632[no description available]medium10
spc-839[no description available]medium10
lenvatinib[no description available]medium10aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
andarine[no description available]medium10acetamides;
anilide
gw843682x[no description available]medium10(trifluoromethyl)benzenes
pd 0325901[no description available]medium10difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin[no description available]medium10benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
ag 14361[no description available]medium10benzimidazoles
sb 265610[no description available]medium10
fr 148083[no description available]medium10aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone		antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
mocetinostat[no description available]medium10aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
osi 930[no description available]medium10aromatic amide
ki 20227[no description available]medium10
scio-469[no description available]medium10aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ssr 69071[no description available]medium10pyridopyrimidine
pi103[no description available]medium10aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
sb 210313[no description available]medium10
gw 4064[no description available]medium10stilbenoid
sa 4503[no description available]medium10
ic 87114[no description available]medium106-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan[no description available]medium10phenylpyridine
tivozanib[no description available]medium10aromatic ether
hki 272[no description available]medium10nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib[no description available]medium10N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532[no description available]medium10
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide[no description available]medium10
rucaparib[no description available]medium10azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib[no description available]medium10aromatic ether
gw0742[no description available]medium10monocarboxylic acid
ps1145[no description available]medium10beta-carbolines
bay 41-8543[no description available]medium10pyrazolopyridine
chir 99021[no description available]medium10aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334[no description available]medium10quinoxaline derivative
way-362450[no description available]medium10indoles
masitinib[no description available]medium101,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines		antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
bx795[no description available]medium10ureas
pazopanib[no description available]medium10aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
sepantronium[no description available]medium10organic cation
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea[no description available]medium10
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide[no description available]medium101,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858[no description available]medium10
aee 788[no description available]medium106-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
saracatinib[no description available]medium10aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
sd-208[no description available]medium10
vx 702[no description available]medium10phenylpyridine
volasertib[no description available]medium10
PB28[no description available]medium10aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
azd 7762[no description available]medium10aromatic amide;
thiophenes
krp-203[no description available]medium10
mk 0354[no description available]medium10
regorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester[no description available]medium10pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one[no description available]medium10methoxybenzenes;
substituted aniline
brivanib[no description available]medium10aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
icg 001[no description available]medium10peptide
mp470[no description available]medium10N-arylpiperazine
nu 7441[no description available]medium10dibenzothiophenes
at 7519[no description available]medium10dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bi 2536[no description available]medium10
danusertib[no description available]medium10piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide[no description available]medium10benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide[no description available]medium10benzamides
abt 869[no description available]medium10aromatic amine;
indazoles;
phenylureas		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
dorsomorphin[no description available]medium10aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066[no description available]medium10
carfilzomib[no description available]medium10epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
gw9508[no description available]medium10aromatic amine
jnj 26854165[no description available]medium10
pf 573228[no description available]medium10quinolines
gw 2580[no description available]medium10
idelalisib[no description available]medium10aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib[no description available]medium103-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile[no description available]medium10benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide[no description available]medium10aromatic amide;
heteroarene
osi 906[no description available]medium10cyclobutanes;
quinolines
ly2109761[no description available]medium10
chir-265[no description available]medium10aromatic ether
motesanib[no description available]medium10pyridinecarboxamide
az-628[no description available]medium10benzamides
trametinib[no description available]medium10acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pf-562,271[no description available]medium10indoles
veliparib[no description available]medium10benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648[no description available]medium10dibenzothiophenes
dactolisib[no description available]medium10imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
palomid 529[no description available]medium10
tosedostat[no description available]medium10carboxylic ester;
hydroxamic acid;
secondary carboxamide
mdv 3100[no description available]medium10(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
ku 60019[no description available]medium10
gsk 461364[no description available]medium10(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide[no description available]medium10
nvp-tae684[no description available]medium10piperidines
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide[no description available]medium10
gsk 269962a[no description available]medium10
a-83-01[no description available]medium10
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one[no description available]medium10indoles
vx-770[no description available]medium10aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone		CFTR potentiator;
orphan drug
buparlisib[no description available]medium10aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480[no description available]medium10
fedratinib[no description available]medium10sulfonamide
gsk690693[no description available]medium101,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024[no description available]medium102-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
ku 0063794[no description available]medium10benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
mTOR inhibitor
azd 7545[no description available]medium10benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
nutlin-3b[no description available]medium10Nutlin;
piperazinone		anticoronaviral agent
pf 04217903[no description available]medium10quinolines
gdc 0941[no description available]medium10indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164[no description available]medium10benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
ph 797804[no description available]medium10aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408[no description available]medium10
gsk 1016790a[no description available]medium101-benzothiophenes;
aromatic primary alcohol;
dichlorobenzene;
N-acylpiperazine;
sulfonamide;
tertiary carboxamide		TRPV4 agonist
olaparib[no description available]medium10cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720[no description available]medium10
plx 4720[no description available]medium10aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
cx 4945[no description available]medium10
cudc 101[no description available]medium10
mln 8237[no description available]medium10benzazepine
lde225[no description available]medium10aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449[no description available]medium10benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
sgx 523[no description available]medium10aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine		c-Met tyrosine kinase inhibitor;
nephrotoxic agent
bms 777607[no description available]medium10aromatic amide
sgi 1776[no description available]medium10imidazoles
pci 32765[no description available]medium10acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib[no description available]medium10(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
amg 900[no description available]medium10
mk-1775[no description available]medium10piperazines
bag956[no description available]medium10
quizartinib[no description available]medium10benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester[no description available]medium10carbamate ester
tak 733[no description available]medium10
mk 2206[no description available]medium10organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax[no description available]medium10aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
sns 314[no description available]medium10ureas
jzl 184[no description available]medium10benzodioxoles
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide[no description available]medium10aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036[no description available]medium10organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
cabozantinib[no description available]medium10aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide[no description available]medium10benzamides
incb-018424[no description available]medium10nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bix 01294[no description available]medium10piperidines
pf 3845[no description available]medium10piperidines
gsk 2126458[no description available]medium10aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
ixazomib[no description available]medium10benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
ldn 193189[no description available]medium10pyrimidines
plx4032[no description available]medium10aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol[no description available]medium10biphenyls
gsk 1363089[no description available]medium10aromatic ether
kin-193[no description available]medium10pyridopyrimidine
bay 869766[no description available]medium10
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester[no description available]medium10carbamate ester
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline[no description available]medium10benzenes;
sulfonamide
cp 466722[no description available]medium10quinazolines
CAY10626[no description available]medium10ureas
thiopental sodium[no description available]medium10organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor
pha 793887[no description available]medium10piperidinecarboxamide
nvp-bsk805[no description available]medium10
xmd 8-92[no description available]medium10pyrimidobenzodiazepineprotein kinase inhibitor
jq1 compound[no description available]medium10carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
jnj38877605[no description available]medium10quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide[no description available]medium10benzothiazoles
torin 1[no description available]medium10N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
ly2940680[no description available]medium10
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea[no description available]medium10ureas
ro 4929097[no description available]medium10dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound		EC 3.4.23.46 (memapsin 2) inhibitor
gsk4112[no description available]medium10
torin 2[no description available]medium10aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline		antineoplastic agent;
mTOR inhibitor
pf-4708671[no description available]medium10
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide[no description available]medium10benzamides;
N-acylpiperidine
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide[no description available]medium10aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
belinostat[no description available]medium10olefinic compound
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate[no description available]medium10carboxylic acid;
pyrroline
a 769662[no description available]medium10biphenyls
LimKi 3[no description available]medium101,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide		LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone[no description available]medium10pyrroles
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole[no description available]medium10dipyrrins
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide[no description available]medium10tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione[no description available]medium10pyrazines
gsk837149a[no description available]medium10
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide[no description available]medium10quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide[no description available]medium10quinazolines
wnt-c59[no description available]medium10
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime[no description available]medium10indanes
chir 258[no description available]medium10
osi 027[no description available]medium10
hli 373[no description available]medium10
pemetrexed[no description available]medium10N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
aprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
xav939[no description available]medium10(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
2-carboxyarabinitol 1-phosphate[no description available]medium10
nintedanib[no description available]medium10
ver 52296[no description available]medium10aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
sb-590885[no description available]medium10aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
pf-477736[no description available]medium10
fenobam[no description available]medium10ureas
captopril[no description available]medium740alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
captopril[no description available]medium748alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
hydrochlorothiazide[no description available]medium10benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
benazepril[no description available]medium10benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
valsartan[no description available]medium10biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
dipyridamole[no description available]medium10piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
digoxin[no description available]medium10cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
temocapril hydrochloride[no description available]medium10dipeptide
enalapril[no description available]high60dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
angiotensin ii[no description available]medium81amino acid zwitterion;
angiotensin II		human metabolite
candesartan cilexetil[no description available]medium30biphenyls
desacetyl-alacepril[no description available]medium70
7-ketocholesterol[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
7-oxo steroid;
cholestanoid		neuroprotective agent
candesartan[no description available]medium10benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
spironolactone[no description available]medium103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
sparfloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
creatine[no description available]medium20glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
atrial natriuretic factor[no description available]medium42polypeptide
natriuretic peptide, brain[no description available]medium21polypeptide
forasartan[no description available]medium20benzenes;
pyridines;
tetrazoles;
triazoles		angiotensin receptor antagonist;
antihypertensive agent
losartan[no description available]medium10biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
transforming growth factor beta[no description available]medium10
cyclic gmp[no description available]medium103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
bradykinin[no description available]medium40oligopeptidehuman blood serum metabolite;
vasodilator agent
isoproterenol[no description available]medium10catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isosorbide dinitrate[no description available]medium11glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
D-fructopyranose[no description available]medium20cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
icatibant[no description available]medium10
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
angiotensin i[no description available]medium20angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
lisinopril[no description available]high30dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
uric acid[no description available]medium20uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
deoxyguanosine[no description available]medium10purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
8-hydroxy-2'-deoxyguanosine[no description available]medium10guanosinesbiomarker
trichlormethiazide[no description available]medium11benzothiadiazine;
sulfonamide antibiotic		antihypertensive agent;
diuretic
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
camostat[no description available]medium11benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
gabexate[no description available]medium11benzoate ester
ramipril[no description available]high10azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
rentiapril[no description available]medium10
aldosterone[no description available]medium3011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
3-mercaptopropionic acid[no description available]medium10mercaptopropanoic acidalgal metabolite
thiazolidines[no description available]medium10thiazolidine
enalaprilat anhydrous[no description available]high10dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
penicillamine[no description available]medium10non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
desoxycorticosterone[no description available]medium1020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
dinoprostone[no description available]medium10prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
6-ketoprostaglandin f1 alpha[no description available]medium10prostaglandins Falphahuman metabolite;
mouse metabolite
ci 906[no description available]low00hydrochlorideantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
quinapril[no description available]low00dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
cilazapril, anhydrous[no description available]low00dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
fosinoprilat[no description available]low00L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
perindoprilat[no description available]medium00dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
corilagin[no description available]low00ellagitannin;
gallate ester		antihypertensive agent;
antioxidant;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
non-steroidal anti-inflammatory drug
zofenopril[no description available]low00aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent
perindopril[no description available]low00alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
quinaprilat[no description available]low00dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
perindopril erbumine[no description available]low00addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
spiraprilat[no description available]medium00azaspiro compound;
dicarboxylic acid;
dipeptide;
dithioketal;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
zofenoprilate[no description available]low00aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
spirapril[no description available]medium00azaspiro compound;
dicarboxylic acid monoester;
dipeptide;
dithioketal;
ethyl ester;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
lotensin[no description available]low00hydrochlorideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
enalapril maleate[no description available]low00maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
benazeprilat[no description available]low00benzazepine;
dicarboxylic acid;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ramiprilat[no description available]medium00azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid;
dipeptide		bradykinin receptor B2 agonist;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor
trandolaprilat[no description available]medium00dicarboxylic acid;
dipeptide;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
human xenobiotic metabolite
imidapril[no description available]medium00dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
imidaprilat[no description available]medium00dicarboxylic acid;
dipeptide;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trandolapril[no description available]medium00dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
nicotianamine[no description available]low00amino acid zwitterion;
nicotianamine		chelator;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
plant metabolite
alanylalanine[no description available]low00dipeptide
gliotoxin[no description available]low00dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor
glycylglycine[no description available]low00dipeptide zwitterion;
dipeptide		human metabolite
moexipril hydrochloride[no description available]low00dipeptide
alitame[no description available]low00dipeptide
glutaurine[no description available]low00dipeptide zwitterion;
dipeptide;
L-glutamine derivative;
sulfonic acid		anticonvulsant;
anxiolytic drug;
hormone;
human metabolite;
mammalian metabolite;
mouse metabolite
leucyltyrosine[no description available]low00dipeptidemetabolite
libenzapril[no description available]low00dipeptide
carbobenzoxyvalylphenylalanine aldehyde[no description available]low00aldehyde;
carbamate ester;
dipeptide		antileishmanial agent;
apoptosis inhibitor;
EC 3.4.22.52 (calpain-1) inhibitor;
EC 3.4.22.53 (calpain-2) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor
leucylleucine[no description available]low00dipeptide;
L-aminoacyl-L-amino acid zwitterion		human metabolite;
Mycoplasma genitalium metabolite
phenylalanylleucine[no description available]low00dipeptide zwitterion;
dipeptide		plant metabolite
leucyl-alanine[no description available]low00dipeptidemetabolite
alanylproline[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
tyrosylleucine[no description available]low00dipeptidemetabolite
Trp-Trp[no description available]low00dipeptideMycoplasma genitalium metabolite
glycyltryptophan[no description available]low00dipeptidemetabolite
glycyltyrosine[no description available]low00dipeptidemetabolite
glycylleucine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
gamma-glutamylglutamate[no description available]low00dipeptidehuman metabolite
alanyltyrosine[no description available]low00dipeptidemetabolite
glycyl-l-phenylalanine[no description available]low00dipeptide zwitterion;
dipeptide		human metabolite;
metabolite
aspartyl-phenylalanine[no description available]low00dipeptidehuman blood serum metabolite;
human xenobiotic metabolite
glycylsarcosine[no description available]low00dipeptide zwitterion;
dipeptide
gamma-glutamyltyrosine[no description available]low00dicarboxylic acid;
dipeptide;
phenols;
primary amino compound;
secondary carboxamide		human metabolite
alanylphenylalanine[no description available]low00dipeptidemetabolite
tryptophylglycine[no description available]low00dipeptidemetabolite
glycylaspartic acid[no description available]low00dipeptidemetabolite
n-glycylglutamic acid[no description available]low00dipeptidemetabolite
beta-aspartylglycine[no description available]low00dipeptide
alpha-glutamyltryptophan[no description available]low00dipeptideangiogenesis modulating agent;
antineoplastic agent;
immunomodulator;
metabolite
histidylglycine[no description available]low00dipeptidemetabolite
histidinoalanine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
valylvaline[no description available]low00dipeptideMycoplasma genitalium metabolite
tabtoxin[no description available]low00dipeptide;
L-threonine derivative;
monobactam;
secondary alcohol		bacterial metabolite;
toxin
gamma-glutamylphenylalanine[no description available]low00dipeptidehuman urinary metabolite
anserine[no description available]low00beta-alanine derivative;
dipeptide;
zwitterion		animal metabolite;
mouse metabolite
maculosin[no description available]low00dipeptide;
homodetic cyclic peptide;
phenols;
pyrrolopyrazine		metabolite
kyotorphin[no description available]low00dipeptide
glycylglutamine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite;
protective agent
alanylglutamine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
lysyllysine[no description available]low00dipeptideMycoplasma genitalium metabolite
alanylglutamic acid[no description available]low00dipeptide
chrysobactin[no description available]low00catechols;
dipeptide;
monocarboxylic acid;
primary alcohol;
primary amino compound		bacterial metabolite;
siderophore
n-acetylglutaminylglutamine amide[no description available]low00dipeptide
b 581[no description available]low00dipeptideEC 2.5.1.58 (protein farnesyltransferase) inhibitor;
peptidomimetic
carbocysteine-lysine[no description available]low00dipeptide
aspartame[no description available]low00carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
cysteinyltyrosine[no description available]low00dipeptide
phenylalanylarginine[no description available]low00dipeptidemetabolite
gamma-glutamylglutamine[no description available]low00dipeptidehuman metabolite
arginylproline[no description available]low00dipeptide
prolylarginine[no description available]low00dipeptidemetabolite
phenylalanylglutamate[no description available]low00dipeptidemetabolite
aspartylglycine[no description available]low00dipeptidemetabolite
aspartylglutamate[no description available]low00dipeptidemetabolite
u-47929[no description available]low00alkaloid;
aziridines;
dipeptide;
pyrrolidines		antibacterial agent;
bacterial metabolite;
DNA synthesis inhibitor
arginylarginine[no description available]low00dipeptideMycoplasma genitalium metabolite
histidylphenylalanine[no description available]low00dipeptide
cysteinylcysteine[no description available]low00dipeptideMycoplasma genitalium metabolite
prolyl-tyrosine[no description available]low00dipeptidemetabolite
histidylproline[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
pyroglutamylleucine[no description available]low00dipeptide
glycylphenylalanine 2-naphthylamide[no description available]low00dipeptide;
N-(2-naphthyl)carboxamide		chromogenic compound
leucylarginine[no description available]low00dipeptidemetabolite
gamma-glu-asp[no description available]low00dipeptide
aspartyl-proline[no description available]low00dipeptide
lysylproline[no description available]low00dipeptidemetabolite
brevianamide f[no description available]low00dipeptide;
indoles;
pyrrolopyrazine		metabolite
isospaglumic acid[no description available]low00dipeptidehuman metabolite
histidylleucine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
phenylalanylserine[no description available]low00dipeptidemetabolite
prolylglutamic acid[no description available]low00dipeptidemetabolite
4-aminobenzoylglutamic acid[no description available]low00dicarboxylic acid;
dipeptide;
N-acyl-L-alpha-amino acid;
substituted aniline
carnosine[no description available]low00amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
cysteinylglycine[no description available]low00dipeptide zwitterion;
dipeptide		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite
glutamyl-glutamic acid[no description available]low00dipeptideMycoplasma genitalium metabolite
temocapril[no description available]low00dipeptide
phosphoramidon[no description available]low00deoxyaldohexose phosphate;
dipeptide		bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
histidyl-proline diketopiperazine[no description available]low00dipeptide;
homodetic cyclic peptide;
imidazoles;
pyrrolopyrazine		anti-inflammatory agent;
dopamine uptake inhibitor;
human blood serum metabolite
isoleucylvaline[no description available]low00dipeptidemetabolite
aspartyl-aspartic acid[no description available]low00dipeptideMycoplasma genitalium metabolite
Phe-Tyr[no description available]low00dipeptidemetabolite
omapatrilat[no description available]low00dipeptide
n-glycylalanine[no description available]low00dipeptidemetabolite
glycylvaline[no description available]low00dipeptidehuman metabolite
glycylproline[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
cysteinylproline[no description available]low00dipeptidemetabolite
glycyllysine[no description available]low00dipeptidemetabolite
methionyltryptophan[no description available]low00dipeptidemetabolite
prolyl-4-hydroxyproline[no description available]low00dipeptide
seryl-proline[no description available]low00dipeptidemetabolite
leukotriene d4[no description available]low00dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite
leukotriene f-4[no description available]low00dipeptide;
leukotriene;
organic sulfide		human metabolite
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester[no description available]low00carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
alanylalanine[no description available]low00dipeptide zwitterion;
dipeptide		Mycoplasma genitalium metabolite
imidapril[no description available]low00dipeptide
n-acetyl-beta-glucosaminyl-n-acetylmuramyl-alanylisoglutamine[no description available]low00dipeptide
phenylalanylalanine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
alpha-aspartylalanine[no description available]low00dipeptidemetabolite
prolylglycine[no description available]low00dipeptide zwitterion;
dipeptide
aspartyllysine[no description available]low00dipeptidemetabolite
arginyllysine[no description available]low00dipeptidemetabolite
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate[no description available]low00dipeptideanticoronaviral agent
bentiromide[no description available]low00dipeptidediagnostic agent;
indicator;
reagent
golotimod[no description available]low00dipeptide
phenylalanylglycine[no description available]low00dipeptidemetabolite
leucyl-phenylalanine[no description available]low00dipeptidemetabolite
glutamylalanine[no description available]low00dipeptidemetabolite
glutaminyl-glycine[no description available]low00dipeptidemetabolite
methionylglycine[no description available]low00dipeptidemetabolite
phenylalanylphenylalanine[no description available]low00dipeptide;
L-aminoacyl-L-amino acid zwitterion		human blood serum metabolite;
Mycoplasma genitalium metabolite
histidylhistidine[no description available]low00dipeptideMycoplasma genitalium metabolite
valylleucine[no description available]low00dipeptidemetabolite
phenylalanyl-valine[no description available]low00dipeptidemetabolite
alanylglycine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
valyltyrosine[no description available]low00dipeptidemetabolite
alpha-glutamyltryptophan[no description available]low00dipeptidemetabolite
lysylglutamic acid[no description available]low00dipeptidemetabolite
methionylglutamic acid[no description available]low00dipeptidemetabolite
seryl-histidine[no description available]low00dipeptidemetabolite
Ala-Lys[no description available]low00dipeptidemarine metabolite
arginyl-glutamine[no description available]low00dipeptidemetabolite
phenylalanylproline[no description available]low00dipeptidemetabolite
lysylglycine[no description available]low00dipeptidemetabolite
glycylhistidine[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
cyclo(leucyl-prolyl)[no description available]low00dipeptide;
homodetic cyclic peptide;
pyrrolopyrazine		bacterial metabolite;
marine metabolite
prolylisoleucine[no description available]low00dipeptidemetabolite
isoleucyl-tyrosine[no description available]low00dipeptidemetabolite
prolyl-serine[no description available]low00dipeptidemetabolite
neotame[no description available]low00dipeptideenvironmental contaminant;
sweetening agent;
xenobiotic
prolylvaline[no description available]low00dipeptidemetabolite
tryprostatin b[no description available]low00dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine
n-acetylcarnosine[no description available]low00dipeptidemetabolite
tryprostatin a[no description available]low00aromatic ether;
dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine		breast cancer resistance protein inhibitor
s-nitrosocysteinylglycine[no description available]low00dipeptide;
nitroso compound;
nitrosothio compound
homocarnosine[no description available]low00dipeptide zwitterion;
dipeptide;
homocarnosine;
L-histidine derivative;
N-acyl-L-alpha-amino acid anion;
N-acyl-L-alpha-amino acid		human metabolite
gsk221149a[no description available]low00dipeptide
vx 765[no description available]low00dipeptide
prolyl-proline[no description available]low00dipeptidehuman urinary metabolite;
Mycoplasma genitalium metabolite
epelsiban[no description available]low00dipeptide
tyropeptin a[no description available]low00dipeptide
leucylproline[no description available]low00dipeptide zwitterion;
dipeptide		metabolite
tyrosyl-proline[no description available]low00dipeptide
id[no description available]low00dipeptide
gap 134[no description available]low00dipeptide
vanchrobactin[no description available]low00catechols;
dipeptide;
guanidines;
monocarboxylic acid;
primary alcohol;
triol		bacterial metabolite;
marine metabolite;
siderophore
syringolin a[no description available]low00dipeptide
l-ala-gamma-d-glu-meso-diaminopimelic acid[no description available]low00dipeptide
Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate[no description available]low00dipeptideanticoronaviral agent
birinapant[no description available]low00dipeptide
RF9[no description available]low00dipeptidekisspeptin receptor agonist;
neuropeptide FF receptor agonist;
neuropeptide FF receptor antagonist
abt-267[no description available]low00aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Aging0low20
Alloxan Diabetes0low10
Anesthesia0low10
Angina Pectoris0medium11
Angioedema0low10
Angioneurotic Edema0low10
Angor Pectoris0medium11
Anterior Circulation Transient Ischemic Attack0low10
Aortic Diseases0low20
Aortic Incompetence0low10
Aortic Regurgitation0low10
Aortic Valve Incompetence0low10
Aortic Valve Insufficiency0low10
Arteriosclerosis0low30
Blood Pressure, High0medium272
Body Weight0medium41
Brain Stem Ischemia, Transient0low10
Brain Stem Transient Ischemic Attack0low10
Brain TIA0low10
Brainstem Ischemia, Transient0low10
Brainstem Transient Ischemic Attack0low10
Canine Diseases0low30
Cardiac Failure0medium53
Cardiac Hypertrophy0low20
Cardiomegaly0low20
Carotid Circulation Transient Ischemic Attack0low10
Cerebral Ischemia, Transient0low10
Chronic Kidney Failure0low10
Compensatory Hyperinsulinemia0low10
Complication, Postoperative0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Heart Failure0medium53
Crescendo Transient Ischemic Attacks0low10
Diabetes Mellitus, Adult-Onset0low20
Diabetes Mellitus, Experimental0low10
Diabetes Mellitus, Ketosis-Resistant0low20
Diabetes Mellitus, Maturity-Onset0low20
Diabetes Mellitus, Non Insulin Dependent0low20
Diabetes Mellitus, Non-Insulin-Dependent0low20
Diabetes Mellitus, Noninsulin Dependent0low20
Diabetes Mellitus, Noninsulin-Dependent0low20
Diabetes Mellitus, Slow-Onset0low20
Diabetes Mellitus, Stable0low20
Diabetes Mellitus, Type 20low20
Diabetes Mellitus, Type II0low20
Diabetic Glomerulosclerosis0medium31
Diabetic Kidney Disease0medium31
Diabetic Nephropathies0medium31
Diabetic Nephropathy0medium31
Disease Models, Animal0low30
Dog Diseases0low30
Electrolytes0low10
Elevated Cholesterol0low20
End-Stage Kidney Disease0low10
End-Stage Renal Disease0low10
Endogenous Hyperinsulinism0low10
Enlarged Heart0low20
ESRD0low10
Exogenous Hyperinsulinism0low10
Experimental Diabetes Mellitus0low10
Fallot's Tetralogy0low10
Fasting Hypoglycemia0low10
Fever, Zika0low10
Glomerulosclerosis, Diabetic0medium31
Glucose Intolerance0low10
Goldblatt Syndrome0low30
Heart Decompensation0medium53
Heart Enlargement0low20
Heart Failure0medium53
Heart Failure, Congestive0medium53
Heart Failure, Left-Sided0medium53
Heart Failure, Right-Sided0medium53
Heart Hypertrophy0low20
Hemorrhage, Subarachnoid0low10
High Cholesterol Levels0low20
Hypercholesteremia0low20
Hypercholesterolemia0low20
Hyperinsulinemia0low10
Hyperinsulinism0low10
Hypertension0medium272
Hypertension, Goldblatt0low30
Hypertension, Renal0low20
Hypertension, Renovascular0low30
Hypertrophy, Left Ventricular0medium21
Hypoglycemia0low10
Impaired Glucose Tolerance0low10
Inflammation0low10
Innate Inflammatory Response0low10
Insulin Resistance0low40
Insulin Sensitivity0low40
Intracapillary Glomerulosclerosis0medium31
Ischemic Attack, Transient0low10
Kidney Diseases0low10
Kidney Failure, Chronic0low10
Kimmelstiel-Wilson Disease0medium31
Kimmelstiel-Wilson Syndrome0medium31
Left Ventricular Hypertrophy0medium21
Left-Sided Heart Failure0medium53
Leukocytopenia0low10
Leukopenia0low10
Licheniform Eruptions0low10
Lichenoid Eruptions0low10
Maturity-Onset Diabetes0low20
Maturity-Onset Diabetes Mellitus0low20
Microglossia0low10
Mitral Incompetence0low20
Mitral Insufficiency0low20
Mitral Regurgitation0low20
Mitral Valve Incompetence0low20
Mitral Valve Insufficiency0low20
Mitral Valve Regurgitation0low20
MODY0low20
Muscle Relaxation0low10
Myocardial Failure0medium53
NIDDM0low20
Nodular Glomerulosclerosis0medium31
Noninsulin-Dependent Diabetes Mellitus0low20
Ovarian Hyperstimulation Syndrome0low10
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous0low10
Perinatal Subarachnoid Hemorrhage0low10
Postabsorptive Hypoglycemia0low10
Posterior Circulation Transient Ischemic Attack0low10
Postoperative Complications0low10
Postprandial Hypoglycemia0low10
Proteinuria0medium21
Quincke's Edema0low10
Reactive Hypoglycemia0low10
Regurgitation, Aortic Valve0low10
Renal Disease, End-Stage0low10
Renal Failure, Chronic0low10
Renal Failure, End-Stage0low10
Right-Sided Heart Failure0medium53
SAH (Subarachnoid Hemorrhage)0low10
Stenocardia0medium11
Streptozocin Diabetes0low10
Streptozotocin Diabetes0low10
Subarachnoid Hemorrhage0low10
Subarachnoid Hemorrhage, Aneurysmal0low10
Subarachnoid Hemorrhage, Intracranial0low10
Subarachnoid Hemorrhage, Spontaneous0low10
Tetralogy of Fallot0low10
Tetralogy, Fallot's0low10
TIA (Transient Ischemic Attack)0low10
Tongue Diseases0low10
Transient Ischemic Attack0low10
Transient Ischemic Attack, Anterior Circulation0low10
Transient Ischemic Attack, Brain Stem0low10
Transient Ischemic Attack, Brainstem0low10
Transient Ischemic Attack, Carotid Circulation0low10
Transient Ischemic Attack, Posterior Circulation0low10
Transient Ischemic Attack, Vertebrobasilar Circulation0low10
Transient Ischemic Attacks, Crescendo0low10
Type 2 Diabetes0low20
Type 2 Diabetes Mellitus0low20
Uremia0medium21
Urticaria, Giant0low10
Ventricular Hypertrophy, Left0medium21
Vertebrobasilar Circulation Transient Ischemic Attack0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Pharmacokinetics (2)

ArticleYear
Pharmacodynamics of alacepril in healthy cats.
Journal of feline medicine and surgery, Volume: 19, Issue: 6		2017
Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states.
Clinical pharmacology and therapeutics, Volume: 38, Issue: 4		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Effects of high-dose alacepril on left atrial pressure and central aortic pressure in awake dogs with mitral valve regurgitation.
Veterinary journal (London, England : 1997), Volume: 245		2019
Pharmacodynamics of alacepril in healthy cats.
Journal of feline medicine and surgery, Volume: 19, Issue: 6		2017
Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states.
Clinical pharmacology and therapeutics, Volume: 38, Issue: 4		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]